DadFinStart your free week
DadFin › Stocks › Healthcare › FENC

Fennec Pharmaceuticals Inc. (FENC) stock score

Healthcare · Biotechnology · United States

$12.76 ▲ +9.81% today

59.6
Dad Score, out of 100
middling

Fennec Pharmaceuticals Inc. (FENC) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 59.6 out of 100 on the Dad Score, a middling reading that places the business ahead of 60% of the 5,684 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #323 of 956. Its strongest axes are price action, risk and conviction; its weakest are growth and liquidity.

Scores from the run of Nov 15, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Average
Growth
Below average
Price action
Strong
Risk
Above average
Conviction
Above average
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)11.3×
Dividend yield0.00%
Return on capital-12.6%
Operating margin5.6%
Revenue growth (YoY)-6.1%
FCF yield-3.3%
Net debt / EBITDA-12.74×
Piotroski F-Score1 / 9
52-week change+32.8%
Market cap$410M
Next earnings—

What subscribers see on FENC

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate75.0good$136.6B
REGNRegeneron Pharmaceuticals, Inc.98.6strong$98.8B
MRNAModerna, Inc.31.8weak$90.4B
ARGXargenx SE86.7strong$60.4B
ONCBeOne Medicines AG95.0strong$47.6B
RPRXRoyalty Pharma plc98.2strong$39.9B
RVMDRevolution Medicines, Inc.44.8middling$37.3B
GMABGenmab A/S63.2middling$31.7B

Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Nov 15, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.